|
Colorectal cancer is one of the leading causes of cancer mortality worldwide. Patients diagnosed with metastatic colorectal cancer have a poor prognosis and the available therapies are limited. In recent years, as an attempt to improve the survival rates of patients, new targeted biological therapies have been developed, namely EGFR-targeted therapies, and used in combination with the standard chemotherapy regimens. However, such therapies are only efficient in a subgroup of patients. It is therefore urgent to unravel new therapy approaches. The current work focuses on the investigation of alternative therapy strategies for colorectal cancer and on the identification of putative biomarkers able to predict therapy resistance. |